AR059738A1 - Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos - Google Patents

Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos

Info

Publication number
AR059738A1
AR059738A1 ARP070100899A ARP070100899A AR059738A1 AR 059738 A1 AR059738 A1 AR 059738A1 AR P070100899 A ARP070100899 A AR P070100899A AR P070100899 A ARP070100899 A AR P070100899A AR 059738 A1 AR059738 A1 AR 059738A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
aryl
heterocyclyl
meridamicine
Prior art date
Application number
ARP070100899A
Other languages
English (en)
Spanish (es)
Inventor
Edmund Idris Graziani
Kevin Pong
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR059738A1 publication Critical patent/AR059738A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
ARP070100899A 2006-03-07 2007-03-05 Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos AR059738A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77994006P 2006-03-07 2006-03-07

Publications (1)

Publication Number Publication Date
AR059738A1 true AR059738A1 (es) 2008-04-23

Family

ID=38289934

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100899A AR059738A1 (es) 2006-03-07 2007-03-05 Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos

Country Status (19)

Country Link
US (1) US7745457B2 (enExample)
EP (1) EP1991551A1 (enExample)
JP (1) JP2009529049A (enExample)
KR (1) KR20080099317A (enExample)
CN (1) CN101426796A (enExample)
AR (1) AR059738A1 (enExample)
AU (1) AU2007223962A1 (enExample)
BR (1) BRPI0708611A2 (enExample)
CA (1) CA2643350A1 (enExample)
CR (1) CR10272A (enExample)
EC (1) ECSP088718A (enExample)
IL (1) IL193414A0 (enExample)
MX (1) MX2008011312A (enExample)
NO (1) NO20083695L (enExample)
PE (1) PE20081550A1 (enExample)
RU (1) RU2008132779A (enExample)
TW (1) TW200804400A (enExample)
WO (1) WO2007103347A1 (enExample)
ZA (1) ZA200807678B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828203A2 (en) * 2004-12-20 2007-09-05 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
RU2394036C2 (ru) * 2004-12-20 2010-07-10 Вайет Аналоги рапамицина и их применение при лечении неврологических, пролиферативных и воспалительных заболеваний

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302016D0 (en) 1993-02-02 1993-03-17 Sandoz Ltd Compounds
GB9318144D0 (en) 1993-09-01 1993-10-20 Sandoz Ltd Organic compounds
EP0729471A1 (en) 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US20050197356A1 (en) * 2004-03-02 2005-09-08 Wyeth Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
BRPI0508224A (pt) 2004-03-02 2007-07-17 Wyeth Corp composto ou um sal farmaceuticamente aceitável do mesmo, cepa de actinomiceto, isolado de uma cepa, métodos para a produção de um macrolìdeo e de um composto, produto, composição, métodos de tratamento de um mamìfero e de um distúrbio neurológico, e, uso de um composto
JP2008501342A (ja) 2004-06-03 2008-01-24 ワイス 複合ポリケチドを生成するための生合成遺伝子クラスター
US7595187B2 (en) * 2004-11-12 2009-09-29 Wyeth Elaiophylin biosynthetic gene cluster
EP1828203A2 (en) 2004-12-20 2007-09-05 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
RU2394036C2 (ru) 2004-12-20 2010-07-10 Вайет Аналоги рапамицина и их применение при лечении неврологических, пролиферативных и воспалительных заболеваний

Also Published As

Publication number Publication date
ZA200807678B (en) 2009-08-26
US7745457B2 (en) 2010-06-29
AU2007223962A1 (en) 2007-09-13
KR20080099317A (ko) 2008-11-12
RU2008132779A (ru) 2010-04-20
EP1991551A1 (en) 2008-11-19
CA2643350A1 (en) 2007-09-13
CR10272A (es) 2008-10-03
MX2008011312A (es) 2008-09-12
US20070213525A1 (en) 2007-09-13
WO2007103347A1 (en) 2007-09-13
ECSP088718A (es) 2008-10-31
BRPI0708611A2 (pt) 2011-06-07
TW200804400A (en) 2008-01-16
NO20083695L (no) 2008-10-03
CN101426796A (zh) 2009-05-06
PE20081550A1 (es) 2008-12-31
IL193414A0 (en) 2009-05-04
JP2009529049A (ja) 2009-08-13

Similar Documents

Publication Publication Date Title
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
ES2634490T3 (es) Derivados de ácido napht-2-ylacetico para tratar el sida
CL2011003302A1 (es) Compuestos derivados de amida del acido alquil-sulfonico; composicion farmaceutica; uso de los compuestos como moduladores de la disfuncion de glutamato para prevenir o tratar trastornos neurologicos y psiquiatricos como esquizofrenia, enfermedad de alzheimer, trastornos de deficit de atencion/hiperactividad, perdida de audicion, entre otros.
AR068510A1 (es) Derivados de 4-fenil-1h-piridin-2-ona - 1,3 disustituidos, composiciones farmaceuticas que los contienen y usos de los mismos para tratar o prevenir trastornos del sistema nervioso central.
PE20151651A1 (es) Derivado de tetrahidroimidazol[1,5-d][1,4]oxazepina
AR068512A1 (es) Derivados de 4-aril-1h-piridin-2-onas disustituidas, composiciones farmaceuticas que las contienen y usos de las mismas para tratar o prevenir trastornos del sistema nervioso central
PE20251288A1 (es) Compuestos heterociclicos como inmunomoduladores
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
CR9721A (es) Compuestos de carbamato para utilizar en el tratamiento de desordenes neurodegenerativos
NI201200012A (es) Profármacos que comprenden un conjugado de insulina - conector
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
UY30414A1 (es) Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones.
EA201391158A8 (ru) Диаминиевые соли фенотиазина и их применение
EA200900178A1 (ru) Конденсированные гетероциклические производные и их применение
AR068051A1 (es) Compuestos moduladores de la pi3k quinasa,composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del cancer.
AR101177A1 (es) Inhibidores de la syk
DOP2006000170A (es) Nuevos derivados de espirocromanona
AR070885A1 (es) Compuestos de azaindol para el tratamiento de trastornos del sistema nervioso central
AR065815A1 (es) Compuestos de dihidroindazol en el tratamiento de trastornos del hierro
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
AR065464A1 (es) Derivados de nicotinamida. composiciones farmaceuticas
MX2021011118A (es) Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2.
CL2019001041A1 (es) Compuestos terapéuticos y métodos para utilizarlos.
PE20121523A1 (es) Metodo de tratamiento

Legal Events

Date Code Title Description
FB Suspension of granting procedure